Show simple item record

Effectiveness of initiating extrafine-particle versus fine-particle inhaled corticosteroids as asthma therapy in the Netherlands

dc.contributor.authorvan der Molen, Thys
dc.contributor.authorPostma, Dirkje S
dc.contributor.authorMartin, Richard J
dc.contributor.authorHerings, Ron M C
dc.contributor.authorOverbeek, Jetty A
dc.contributor.authorThomas, Victoria
dc.contributor.authorMiglio, Cristiana
dc.contributor.authorDekhuijzen, Richard
dc.contributor.authorRoche, Nicolas
dc.contributor.authorGuilbert, Theresa
dc.contributor.authorIsrael, Elliot
dc.contributor.authorvan Aalderen, Wim
dc.contributor.authorHillyer, Elizabeth V
dc.contributor.authorvan Rysewyk, Simon
dc.contributor.authorPrice, David B
dc.date.accessioned2016-06-10T14:40:13Z
dc.date.available2016-06-10T14:40:13Z
dc.date.issued2016-05-17
dc.identifier68156103
dc.identifierfc525a7d-c571-4959-b78c-4518636ebaaa
dc.identifier27184175
dc.identifier84969144802
dc.identifier.citationvan der Molen , T , Postma , D S , Martin , R J , Herings , R M C , Overbeek , J A , Thomas , V , Miglio , C , Dekhuijzen , R , Roche , N , Guilbert , T , Israel , E , van Aalderen , W , Hillyer , E V , van Rysewyk , S & Price , D B 2016 , ' Effectiveness of initiating extrafine-particle versus fine-particle inhaled corticosteroids as asthma therapy in the Netherlands ' , BMC Pulmonary Medicine , vol. 16 , no. 1 , 80 . https://doi.org/10.1186/s12890-016-0234-0en
dc.identifier.issn1471-2466
dc.identifier.urihttp://hdl.handle.net/2164/6107
dc.descriptionAcknowledgements Gokul Gopalan (a Senior Global Medical Director [Respiratory], at Teva Pharmaceuticals, Frazer, PA, US, at the time of this study), assisted with study design. Funding Funds to acquire the dataset from the Pharmo Institute for Drug Outcomes Research (Utrecht, the Netherlands) were provided by RiRL. The study received institutional support from Teva Pharmaceuticals Europe B.V. Gokul Gopalan, a Senior Global Medical Director (Respiratory), at Teva Pharmaceuticals, Frazer, PA, US, at the time of this study, assisted with study design, but neither Teva Pharmaceuticals Europe B.V. nor Teva Pharmaceuticals, Frazer, PA, US, contributed, either in part or in whole, to the collection, analysis, or interpretation of study data, manuscript writing, or the decision to submit the manuscript for publication. Erratum The original version of this article unfortunately contained errors that have since been corrected. The word “pharmo” has been fully capitalised to “PHARMO” throughout the article. The reference to Table 2 in the first and second sentence under the Outcomes heading has been replaced with Fig. 3. Under the Abbreviations heading ‘extrafine-particle’ was repeated, this has been corrected to ‘EF-HFA-BDP [Qvar®]: extrafine-particle hydrofluoroalkane beclomethasone dipropionate’. The competing interests of Nicolas Roche and Theresa Guibert have been amended. Academic affiliations for Dirkje S. Postma (2), Richard J. Martin (3), Ron M.C. Herrings (4), Jetty Overbeek (4), and Nicolas Roche (7) have been corrected. Figure 3 in the online and pdf version did not match, this been amendeden
dc.format.extent1031718
dc.language.isoeng
dc.relation.ispartofBMC Pulmonary Medicineen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectAsthmaen
dc.subjectEffectivenessen
dc.subjectExtrafine-particleen
dc.subjectFine-particleen
dc.subjectInhaled corticosteroidsen
dc.subjectR Medicineen
dc.subject.lccRen
dc.titleEffectiveness of initiating extrafine-particle versus fine-particle inhaled corticosteroids as asthma therapy in the Netherlandsen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.description.statusPeer revieweden
dc.identifier.doi10.1186/s12890-016-0234-0


Files in this item

Thumbnail
Name:
art_3A10.1186_2Fs12890_016_023 ...
Size:
1007.Kb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record